Ko Chih-Jan, Chien Su-Yu, Chou Chen-Te, Chen Li-Sheng, Chen Mei-Ling, Chen Yao-Li
Department of General Surgery, Changhua Christian Hospital, Taiwan.
Can J Gastroenterol. 2011 Sep;25(9):485-91. doi: 10.1155/2011/790528.
Small hepatocellular carcinoma (HCC) affects millions of individuals worldwide. Surveillance of high-risk patients increases the early detection of small HCC.
To identify prognostic factors affecting the overall survival (OS) and recurrence-free survival (RFS) of patients with small HCC.
The present prospective study enrolled 140 Taiwanese patients with stage I or stage II small HCC. Clinical parameters of interest included operation type, tumour size, tumour histology, Child- Pugh class, presence of hepatitis B surface antigen and liver cirrhosis, hepatitis C status, alpha-fetoprotein, total bilirubin and serum albumin levels, and administration of antiviral and salvage therapies.
Tumour size correlated significantly with poorer OS in patients with stage I small HCC (P=0.014); however, patients with stage II small HCC experienced a significantly poorer RFS (P=0.033). OS rates did not differ significantly between patients with stage I and stage II small HCC. Tumour margins, tumour histology and cirrhosis did not significantly affect OS or RFS (P>0.05).
Increasing tumour size has generally been associated with poorer prognoses in cases of HCC. The present study verified the relationship between small HCC tumour size and OS; however, a reduction in OS with increasing tumour size was demonstrated for patients with stage I - but not for stage II - small HCC.
Patients with stage II small HCC may benefit from aggressive surveillance for tumour recurrence and appropriate salvage treatment. Further studies are needed for additional stratification of stage I patients to identify those at increased risk of death.
小肝细胞癌(HCC)影响着全球数百万人。对高危患者进行监测可提高小HCC的早期检测率。
确定影响小HCC患者总生存期(OS)和无复发生存期(RFS)的预后因素。
本前瞻性研究纳入了140例台湾I期或II期小HCC患者。感兴趣的临床参数包括手术类型、肿瘤大小、肿瘤组织学、Child-Pugh分级、乙肝表面抗原和肝硬化的存在情况、丙肝状态、甲胎蛋白、总胆红素和血清白蛋白水平,以及抗病毒和挽救治疗的应用情况。
肿瘤大小与I期小HCC患者较差的OS显著相关(P=0.014);然而,II期小HCC患者的RFS显著较差(P=0.033)。I期和II期小HCC患者的OS率无显著差异。肿瘤边缘、肿瘤组织学和肝硬化对OS或RFS无显著影响(P>0.05)。
在HCC病例中,肿瘤大小增加通常与较差的预后相关。本研究证实了小HCC肿瘤大小与OS之间的关系;然而,I期小HCC患者显示随着肿瘤大小增加OS降低,而II期小HCC患者并非如此。
II期小HCC患者可能从积极的肿瘤复发监测和适当的挽救治疗中获益。需要进一步研究对I期患者进行额外分层,以识别死亡风险增加的患者。